Advicenne SA

Advicenne is a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for rare kidney diseases. Founded in 2007, the company's mission is to improve the lives of patients, from early childhood through adulthood, by addressing unmet medical needs in rare renal conditions. Advicenne is headquartered in Paris, France.

The company's lead product is Sibnayal® (also known as ADV7103), a prolonged-release oral formulation combining potassium citrate and potassium bicarbonate. This therapy is designed for the chronic management of rare renal and metabolic disorders, specifically targeting distal renal tubular acidosis (dRTA) and cystinuria. Advicenne's products are available in multiple European markets, and the company is actively pursuing expansion into additional international territories, including North America (US and Canada) and the United Arab Emirates.

Recent notable developments include the marketing approval and reimbursement for Sibnayal® in the United Arab Emirates in January 2026, and its official reimbursement by the French social security system for dRTA in February 2026. In November 2025, Advicenne submitted a New Drug Application (NDA) for Sibnayal (ADV7103) for dRTA in the United States, which the FDA accepted for review with a target action date of September 3, 2026. The FDA's acceptance of European data for the filing significantly reduces the need for additional US clinical studies. Led by CEO Didier Laurens, Advicenne reported 2025 annual product sales of €5.8 million, an 18.7% increase over 2024, with European end-market sales of Sibnayal® growing by over 70% to nearly €11 million.